INFLIXIMAB
DrugBank ID: db00065
DrugCentral: infliximab
Synonymous :infliximab (genetical recombination) | infliximab-abda | infliximab-axxq | infliximab-dyyb | infliximab-qbtx
Drug Sentece Context
Table 1. Analysis of context sentence of infliximab gene in 21 abstracts.
| pmid | sentence |
|---|---|
| 32452979 | The patient was treated with infliximab for TNF-α blockade to address both moderately to severely active Crohn’s disease and multisystem inflammatory syndrome in children (MIS-C) temporally related to COVID-19. […] Within hours of infliximab treatment, fever, tachycardia and hypotension resolved. |
| 32513653 | In patients requiring rescue therapy, infliximab with continuing steroids was recommended. |
| 32618402 | Infliximab patients and the one with serious comorbidities showed the worst outcome. |
| 32696108 | Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α (e.g. adalimumab, infliximab), granulocyte-macrophage colony-stimulating factors (e.g. gimsilumab, lenzilumab, namilumab), and convalescent plasma, with promising to negative trials and other data. |
| 32738060 | During the one month after COVID-19 outbreak, 39 (39/56, 69.6%) patients had their infliximab infusion postponed with the mean delay of 3 weeks. |
| 32873696 | In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. […] Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status. |
| 32891582 | Treatment strategies included intravenous immunoglobulin (63%) and intravenous steroids (44%). 29 cases received Infliximab, 47 received IL1 (interleukin) receptor antagonist, and 47 received IL6-receptor antagonist. |
| 32956615 | These include IL-1 antagonists (eg, anakinra), IL-6 receptor blockers (eg, tocilizumab), and anti-TNF agents (eg, infliximab) for children with Kawasaki disease-like phenotype and non-specific presentations. |
| 32997749 | We report the first case of PIMS-TS in a child on established anti-Tumor Necrosis Factor-alpha (anti-TNF-α) therapy; a 10 year-old girl with ulcerative colitis treated with infliximab. […] Infliximab treatment followed and the patient has remained well at follow up. […] Given the uncertainty around therapeutic strategies for PIMS-TS this case supports the need for further investigation into continuing infliximab as a treatment option for the condition. |
| 32999889 | We report the case of an 18-year-old ulcerative colitis patient in sustained clinical remission who 4 days after application of her ongoing therapy with the anti-TNF antibody infliximab developed mild respiratory and abdominal symptoms. |
| 33124705 | During COVID-19 outbreak hospitals were congested and infliximab was interrupted. […] We followed up 56 psoriatic patients who were receiving Infliximab treatment by telephone. |
| 33197261 | Treatment was stratified within an MDT framework and included CSs in all; i.v. immunoglobulin in all; anakinra in 4/19; infliximab in 1/19; and antiviral (aciclovir) in 4/19. |
| 33369063 | All patients had been receiving a biological agent including ustekinumab, etanercept, adalimumab, secukinumab, infliximab, ixekizumab, or certolizumab pegol. |
| 33416268 | Retrospective, observational, cohort study of pediatric patients with IBD, receiving infliximab, adalimumab, vedolizumab, or ustekinumab for at least 2 months. […] One hundred eighty-five children were included (101 [55%] CD, 82 [44%] UC, and 2 [1%] IBDU): 149 received infliximab (IFX) (81%), 88 (48%) adalimumab (ADA), 18 (21%) vedolizumab, and 4 (2%) ustekinumab. |
| 33423942 | About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. |
| 33445833 | For refractory patients, monoclonal antibody to interleukin-6 receptor (tocilizumab), interleukin-1 receptor antagonist (anakinra), or monoclonal antibody to tumor necrosis factor (infliximab) may be recommended. |
| 33452570 | Second-line therapy was needed in 13/22 (group 1) for persisting inflammation or myocardial dysfunction; 12 received infliximab. […] Supportive care, IVIG, and second-line therapy with infliximab were associated with a favorable outcome. […] • IVIG and infliximab therapy were associated with a favorable outcome including resolution of coronary dilatation; only 2/33 received corticosteroids. |
| 33505752 | Although the patient was treated with infliximab, the size of CAA showed a significant decrease in the one-month follow-up. |
| 33519271 | Tocilizumab (IL-6 blocker), Baricitinib (JAKs and AAK1 inhibitor), TNFα inhibitors (Infliximab, Adalimumab, Certolizumab) are currently being evaluated for possible block of the CS. |
| 33584148 | Additional adjunctive therapies (etanercept, infliximab, cyclosporin) may also provide limited benefit, but data is limited to single studies and subgroups of patients with cardiac abnormalities. |